Our Team

Marc Guillet
Executive Director / President

Marc started A Foundation Building Strength in February of 2008 to help his daughter Ava and all patients with Nemaline Myopathy.

Marc is the CEO of Agile Physical Therapy, a company he founded in July of 2002. He is also the director of physical therapy for the Palo Alto Medical Foundation. Marc is on the advisory board for two medical device companies involving technological advances in treatment and rehabilitation of orthopedic and neurologic advances.

Marc is a Board-certified Orthopedic Specialist. His affiliations include: American Physical Therapy Association, National Athletic Training Association, and Orthopedic and Sports Sections of the American Physical Therapy Association. He graduated from Columbia University, New York 1991.

Elyse Stratton
Advisor

Elyse has worked on the clinical and commercial development of companion diagnostic tests from the pharmaceutical, laboratory and patient perspective. She joined Genentech in their diagnostic operations group and was responsible for running an advisory board on EGFR testing methodologies; she worked at Monogram Biosciences on the global launch of an HIV companion diagnostic for Pfizer.  Elyse has experience in market analytics and planning, commercial operations and diagnostic strategy. She currently consults on strategic and commercial issues for large and small biotech companies, as well as the VC community. She earned her MA in International Relations and Economics from Johns Hopkins University and her MPhil in Bioscience Enterprise from University of Cambridge.

Thomas Hyde, MD PhD
Advisor

Thomas M. Hyde, M.D., Ph.D., is the Chief Operating Officer of the Lieber Institute for Brain Development. As such, he directly oversees all functions of the Central Administrative Division, including personnel, finance, information technology, facilities, contracts, and affiliations with outside organizations. In addition to his administrative portfolio, Dr. Hyde manages the Institute’s collection of postmortem human brain samples.  His research focuses on changes in GABA signaling across the stages of normal development and in major psychiatric diseases. Dr. Hyde attended the University of Pennsylvania from 1974–1984. He received a B.A. in Biology in 1978, graduating summa cum laude. He received a joint M.D.-Ph.D. in 1984, with a Ph.D. from the Department of Anatomy. While in this combined degree program, he was the recipient of a University Scholars Award from Penn, and a Medical Scientist Training Program Scholarship from the NIH. He served a general medical internship at the Penn Presbyterian Medical Center from 1984–1985, followed by a neurology residency at Stanford University from 1985–1988. He served as Chief Resident in Neurology the final year of his residency. After leaving California, Dr. Hyde worked in the Clinical Brain Disorders Branch (CBDB) of the intramural program of the National Institute of Mental Health (NIMH). He ran the Neurology Consultation Clinics at St. Elizabeth’s Hospital under the auspices of the NIMH from 1988–1996. From 1996–2010, he worked full-time in the Section on Neuropathology in the CBDB, developing the world’s largest collection of postmortem human brains dedicated to neuropsychiatric disease in general, and schizophrenia in particular.

Mark Eller, PhD
Advisor

Mark G. Eller, Ph.D., is a drug development executive with twenty + years experience in pharmaceutical R&D; including leadership of other VP’s and organizations/departments of 50+ employees. Dr. Eller has extensive experience in pre-clinical studies and the design, execution, analysis and reporting of Phase 1, 2 and 3 clinical trials in the U.S. and Europe. His experience also includes preparation of multiple regulatory filings in U.S., Canada and Europe including IND, MAA, NDA, and CTD submissions leading to approvals. Mark has participated in 6 FDA Advisory Committee meetings, twice as a primary presenter. He is co-inventor on 4 patents in drug discovery and development.

Willie Quinn
Director

Willie Quinn is a life sciences executive with a passion for making a difference. Mr. Quinn is CFO and SVP Corporate Development at Sunesis Pharmaceuticals (NASDAQ:SNSS), a clinical-stage biopharmaceutical company developing new oncology therapeutics. Previously, he was CEO and co-founder of Bullet Bio, a private company developing cancer immunotherapies based on technology invented at Stanford University. Prior to Bullet Bio, Willie ran Corporate Development for Jazz Pharmaceuticals, a public specialty pharmaceutical company with experience developing and commercializing drugs for orphan indications (indications with fewer than 200,000 patients in the U.S.). Willie joined Jazz Pharmaceuticals in 2003 and actively participated in the creation of their first business plan, working in various functions such as business development, strategy, and finance over his 8 years at the company. Prior to Jazz Pharmaceuticals, Willie was COO and CFO at Novation Biosciences, a venture-backed startup developing software to extract meaningful information from microarray data.

Willie has an MBA from the Stanford Graduate School of Business and an MA and a BA from Stanford University.

Tom Unger
Director, R&D Committee Chair

Tom is a healthcare innovator, strategist and change agent.  He served Pfizer in a number of senior roles including head of strategy for Pfizer’s Biotherapeutics and Bioinnovation Center.  There, he initiated innovative efforts spanning business strategy, operational change and clinical development programs.

Prior to Pfizer, Tom held a number of senior strategic advisory positions at Aperion Partners, MTM Advisors, Wood Mackenzie and PA Consulting Group.

Tom is cofounder of BioLogic Technologies, Miragen and most recently Naia Pharmaceuticals.  He also cofounded MIT’s NEW Drug Development ParaDIGmS (NEWDIGS) program and still serves on its Executive Committee.

Boris Shimanovsky
Director

Boris’ daughter, Liv has NM and he plans to change that.  Boris has been an executive at multiple startups and currently works as VP of Engineering at Factual, an LA-based location data startup, where he manages a team of approximately 50 engineers.

Boris holds a BS in Physiological Science and an MS in Computer Science, both from UCLA, where he published a paper on hiding data in DNA and also won an award for research involving heart attacks and chaos theory.  He put himself through school working night shifts as an ambulance driver. Boris lives in Los Angeles with his badass wife and three amazing children. He is a lousy philosopher, a mediocre poet, and will someday become a great chef.